Highest-materiality recent filing
Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026
Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026
Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
Surrozen Q3 net loss $71.6M, appoints new CFO
Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13
TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.
Surrozen enters ATM equity offering agreement for up to $50M with TD Cowen
Sales Agreement with TD Securities (USA) LLC to sell up to $50M of common stock at-the-market or in negotiated transactions.
Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP
Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.
Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology
Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.
Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline
Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.
Surrozen raises ~$76.4M in first tranche private placement; appoints Tim Kutzkey to Board
First tranche closed March 26, 2025; gross proceeds ~$76.4M from 6,586,415 Units at $11.60 each.
Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program
Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.
Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413
Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).
Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M
Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024
Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.
Surrozen raises $17.5M in private placement with milestone-triggered warrants
Issues 1,089,033 shares at $15.50 and pre-funded warrants for 40,000 shares at $15.4999.
Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
Upon the recommendation of the Nominating and Corporate Governance Committee, on March 26, 2025, Tim Kutzkey, Ph.D., was appointed to serve as a Class I director of the Company’s Board of Directors
On June 30, 2024, Tim Kutzkey, Ph.D. notified Surrozen, Inc. of his resignation as a member of our board of directors and from all committees of the board of directors on which he served, effective as of June 30, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings